(Q37125182)

18 August 2017

1 reference

title

The discovery of raltegravir, an integrase inhibitor for the treatment of HIV infection (English)

1 reference

18 August 2017

1 reference

Michael Rowley

1

1 reference

18 August 2017

publication date

1 January 2008

1 reference

Progress in medicinal chemistry

18 August 2017

published in

1 reference

18 August 2017

volume

46

1 reference

18 August 2017

page(s)

1-28

1 reference

A novel antiretroviral class (fusion inhibitors) in the management of HIV infection. Present features and future perspectives of enfuvirtide (T-20).

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900001-X

7 January 2021

Therapies. Confronting the limits of success.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900001-X

7 January 2021

Antiretroviral-drug resistance among patients recently infected with HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900001-X

7 January 2021

Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900001-X

7 January 2021

The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900001-X

7 January 2021

A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900001-X

7 January 2021

The therapeutic potential of CXCR4 antagonists in the treatment of HIV infection, cancer metastasis and rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900001-X

7 January 2021

Integrase inhibitors to treat HIV/AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900001-X

7 January 2021

4-Aryl-2,4-dioxobutanoic acid inhibitors of HIV-1 integrase and viral replication in cells

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900001-X

7 January 2021

Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900001-X

7 January 2021

A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900001-X

7 January 2021

Unravelling hepatitis C virus replication from genome to function

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900001-X

7 January 2021

Product inhibition of the hepatitis C virus NS3 protease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900001-X

7 January 2021

Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900001-X

7 January 2021

Retroviral integrases and their cousins

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900001-X

7 January 2021

A general two-metal-ion mechanism for catalytic RNA

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900001-X

7 January 2021

Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900001-X

7 January 2021

Discovery of alpha,gamma-diketo acids as potent selective and reversible inhibitors of hepatitis C virus NS5b RNA-dependent RNA polymerase

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900001-X

7 January 2021

HCV NS5b RNA-dependent RNA polymerase inhibitors: from alpha,gamma-diketoacids to 4,5-dihydroxypyrimidine- or 3-methyl-5-hydroxypyrimidinonecarboxylic acids. Design and synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900001-X

7 January 2021

2-(2-Thienyl)-5,6-dihydroxy-4-carboxypyrimidines as inhibitors of the hepatitis C virus NS5B polymerase: discovery, SAR, modeling, and mutagenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900001-X

7 January 2021

Design and synthesis of 8-hydroxy-[1,6]naphthyridines as novel inhibitors of HIV-1 integrase in vitro and in infected cells

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900001-X

7 January 2021

L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900001-X

7 January 2021

A novel assay for the DNA strand-transfer reaction of HIV-1 integrase

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900001-X

7 January 2021

From dihydroxypyrimidine carboxylic acids to carboxamide HIV-1 integrase inhibitors: SAR around the amide moiety

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900001-X

7 January 2021

Dihydroxypyrimidine-4-carboxamides as novel potent and selective HIV integrase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900001-X

7 January 2021

Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900001-X

7 January 2021

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900001-X

7 January 2021

10.1016/S0079-6468(07)00001-X

Identifiers

DOI

1 reference

18 August 2017

1 reference